These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 30019172)

  • 21. Age progression from vicenarians (20-29 year) to nonagenarians (90-99 year) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography.
    Dahaba AA; Xiao Z; Zhu X; Dong H; Xiong L; Rehak P; Zelzer S; Wang K; Reibnegger G
    J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):145-161. PubMed ID: 32100175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propofol pharmacokinetic and pharmacodynamic profile and its electroencephalographic interaction with remifentanil in children.
    Fuentes R; Cortínez LI; Contreras V; Ibacache M; Anderson BJ
    Paediatr Anaesth; 2018 Dec; 28(12):1078-1086. PubMed ID: 30307663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Simulation Study of Propofol Effect-Site Concentration for Appropriate Sedation in Pediatric Patients Undergoing Brain MRI: Pharmacodynamic Analysis.
    Na SH; Song Y; Kim SY; Byon HJ; Jung HH; Han DW
    Yonsei Med J; 2017 Nov; 58(6):1216-1221. PubMed ID: 29047247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery.
    Przybyłowski K; Tyczka J; Szczesny D; Bienert A; Wiczling P; Kut K; Plenzler E; Kaliszan R; Grześkowiak E
    J Pharmacokinet Pharmacodyn; 2015 Apr; 42(2):111-22. PubMed ID: 25628234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions.
    Edginton AN; Schmitt W; Willmann S
    Adv Ther; 2006; 23(1):143-58. PubMed ID: 16644615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions.
    Bienert A; Wawrzyniak K; Wiczling P; Przybyłowski K; Kokot ZJ; Matysiak J; Pachutko A; Józefowicz M; Kusza K; Grześkowiak E
    J Clin Pharmacol; 2015 Mar; 55(3):307-16. PubMed ID: 25243731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints.
    Blussé van Oud-Alblas HJ; Brill MJE; Peeters MYM; Tibboel D; Danhof M; Knibbe CAJ
    BMC Anesthesiol; 2019 Jan; 19(1):15. PubMed ID: 30669968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A two-compartment effect site model describes the bispectral index after different rates of propofol infusion.
    Björnsson MA; Norberg A; Kalman S; Karlsson MO; Simonsson US
    J Pharmacokinet Pharmacodyn; 2010 Jun; 37(3):243-55. PubMed ID: 20414709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model.
    Barr J; Egan TD; Sandoval NF; Zomorodi K; Cohane C; Gambus PL; Shafer SL
    Anesthesiology; 2001 Aug; 95(2):324-33. PubMed ID: 11506101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus.
    Leal N; Calvo R; Agrad FZ; Lukas JC; de la Fuente L; Suarez E
    J Pharm Pharmacol; 2005 Mar; 57(3):317-25. PubMed ID: 15807987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrathecal fentanyl decreases the optimal effect site concentration of propofol during spinal anaesthesia.
    Lee JS; Kim JS; Kim MK; Kim SH; Kim JY
    Acta Anaesthesiol Scand; 2014 May; 58(5):597-603. PubMed ID: 24628076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol?
    Kim KM; Park S; Kang BJ; Choi BM; Noh GJ; Bang JY
    J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):305-317. PubMed ID: 33415524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypnotic and cardiovascular effects of proprietary and generic propofol formulations do not differ.
    Fassoulaki A; Paraskeva A; Papilas K; Patris K
    Can J Anaesth; 2001 May; 48(5):459-61. PubMed ID: 11394513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The propofol sparing effect of remifentanil: how can it affect our practice?
    Tommasino C
    Minerva Anestesiol; 2008; 74(1-2):3-4. PubMed ID: 18216761
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of the performance of the Marsh model in effect site mode for target controlled infusion of propofol during the maintenance phase of general anaesthesia in an unselected population of neurosurgical patients.
    Cowley NJ; Hutton P; Clutton-Brock TH
    Eur J Anaesthesiol; 2013 Oct; 30(10):627-32. PubMed ID: 23962821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the hemodynamic response to induction and intubation during a target-controlled infusion of propofol with 2 different pharmacokinetic models. A prospective ramdomized trial.
    Ramos Luengo A; Asensio Merino F; Castilla MS; Alonso Rodriguez E
    Rev Esp Anestesiol Reanim; 2015 Nov; 62(9):487-94. PubMed ID: 25600619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model].
    Sepúlveda PO; Mora X
    Rev Esp Anestesiol Reanim; 2012 Dec; 59(10):542-8. PubMed ID: 23040653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.
    Campagna JA; Pojasek K; Grayzel D; Randle J; Raines DE
    Anesthesiology; 2014 Dec; 121(6):1203-16. PubMed ID: 25170571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%].
    Albrecht S; Ihmsen H; Suchodolski K; Frenkel C; Schüttler J
    Anaesthesist; 1999 Nov; 48(11):794-801. PubMed ID: 10631438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic interactions between opioids and propofol.
    Vuyk J
    J Clin Anesth; 1997 Sep; 9(6 Suppl):23S-26S. PubMed ID: 9278851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.